Tennis Elbow Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of Sodium Hyaluronate to Provide Symptomatic Relief of Lateral Epicondylosis (Tennis Elbow)
NCT number | NCT02861183 |
Other study ID # | OVT 16-01 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | September 2025 |
Est. completion date | October 2027 |
Verified date | November 2022 |
Source | Anika Therapeutics, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of Sodium Hyaluronate to provide Symptomatic Relief of Lateral Epicondylosis (Tennis Elbow).
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | October 2027 |
Est. primary completion date | April 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Male or female between 18 and 65 years of age 2. Clinical diagnosis of unilateral lateral epicondylosis defined as: 1. Pain reproducible on palpation of the lateral epicondyle / common extensor origin; and 2. Pain reproducible during resisted wrist extension 3. Subject is symptomatic for at least 6 weeks 4. Subject has pain in the index lateral epicondyle after grip strength testing that measures = 40 mm on a 100 mm VAS 5. Subject must be willing to abstain from other pharmacological and surgical treatments of the index elbow for the duration of the study 6. Subject is willing to discontinue all systemic and/or topical analgesics including NSAIDs, (except the rescue medication oral acetaminophen/paracetamol), for the treatment of lateral epicondylosis at least seven days before the initial treatment injection and through the completion of the study 7. If pain medication is needed during the study, subject is willing to use only acetaminophen/paracetamol (up to a maximum of 3.0 grams per day per the package insert) for the treatment of elbow pain for the duration of the study 8. At least twenty four hours prior to the Baseline Visit and each follow-up visit, the subject must discontinue use of acetaminophen/paracetamol, if used 9. Subject is able to understand and comply with the requirements of the study and voluntarily provides consent Exclusion Criteria: 1. Subjects with a history of hypersensitivity to any of the ingredients in the hyaluronan or an inability to tolerate acetaminophen/paracetamol 2. Subjects in which the investigator believes the anatomical landmarks for injection are unable to be adequately identified 3. Subjects who have a history of surgery to the intra-articular joint of the index elbow and/or history of index elbow dislocation 4. Any diagnosed pathology or trauma that causes pain or symptoms in the index elbow other than lateral epicondylosis (e.g. intra-articular pathology, ligament injury, cervical radiculopathy, radial tunnel syndrome, osteochondral radiocapitellar lesion or posterolateral elbow plica, pain starting after a motor vehicle accident) 5. Hyaluronic acid injections in the index elbow within the last 6 months 6. Steroid injections in the index elbow within the last 3 months 7. Infections or skin diseases in the area of the injection site or elbow joint 8. Known inflammatory or autoimmune disorders, or other pre-existing medical conditions that, in the opinion of the investigator, could impact healing or affect the ability of the subject to complete the study and comply with the study requirements 9. Subject is taking medications at the time of consent which could interfere with the treatment procedure, healing and/or assessments. This includes but is not limited to oral or injectable anticoagulant treatments, anti-aggregant platelet treatment and opioid analgesics. Low dose aspirin (81 mg) used for cardiovascular protection is allowed if a stable regimen is maintained for the duration of the study. 10. Subject is receiving or in litigation for worker's compensation 11. Subject is a woman who is pregnant or breastfeeding at the screening visit or a woman of child bearing potential who refuses to use effective contraception during the course of the study 12. Subject was involved in any other research study involving an investigational product, or a new application of an approved product, within 60 days of signing the Informed Consent Form (ICF) |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Anika Therapeutics, Inc. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in elbow pain after grip as measured by a 100 mm Visual Analog Scale (VAS) at 12 weeks comparing the OVT group to the saline control group | Pain After Grip score was determined by asking the subject "How much pain do you have in your STUDY elbow right now?" and recording their response by placing a mark along a 100mm VAS scale with 0mm=no pain and 100mm=extreme pain. A negative value for change from baseline indicated a reduction in pain. A greater negative value indicates a better outcome. | 12 weeks post injection | |
Secondary | The change from baseline in elbow pain after grip as measured by a 100 mm VAS at 4, 18, and 26 weeks comparing the OVT group to the saline control group | Pain After Grip score was determined by asking the subject "How much pain do you have in your STUDY elbow right now?" and recording their response by placing a mark along a 100mm VAS scale with 0mm=no pain and 100mm=extreme pain. A negative value for change from baseline indicated a reduction in pain. A greater negative value indicates a better outcome. | 4, 18, 26 weeks post-injection | |
Secondary | The change from baseline in elbow pain after grip as measured by a 100 mm VAS through 4-26 weeks using a longitudinal model comparing the OVT group to the saline control group | Pain After Grip score was determined by asking the subject "How much pain do you have in your STUDY elbow right now?" and recording their response by placing a mark along a 100mm VAS scale with 0mm=no pain and 100mm=extreme pain. A negative value for change from baseline indicated a reduction in pain. A greater negative value indicates a better outcome. | 26 weeks post-injection | |
Secondary | The change from baseline in elbow pain at rest as measured by a 100 mm VAS through 4-26 weeks using a longitudinal model comparing the OVT group to the saline control group | Pain After Grip score was determined by asking the subject "How much pain do you have in your STUDY elbow right now?" and recording their response by placing a mark along a 100mm VAS scale with 0mm=no pain and 100mm=extreme pain. A negative value for change from baseline indicated a reduction in pain. A greater negative value indicates a better outcome. | 26 weeks post-injection | |
Secondary | The change from baseline in elbow pain as measured by the Patient-Rated Tennis Elbow Evaluation (PRTEE) Pain and Function Questionnaire through 4-26 weeks using a longitudinal model comparing the OVT group to the saline control group | Pain After Grip score was determined by asking the subject "How much pain do you have in your STUDY elbow right now?" and recording their response by placing a mark along a 100mm VAS scale with 0mm=no pain and 100mm=extreme pain. A negative value for change from baseline indicated a reduction in pain. A greater negative value indicates a better outcome. | 26 weeks post-injection | |
Secondary | The change from baseline in elbow pain as measured by the Disabilities of Arm, Shoulder, and Hand (DASH) Questionnaire through 4-26 weeks using a longitudinal model comparing the OVT group to the saline control group | Pain After Grip score was determined by asking the subject "How much pain do you have in your STUDY elbow right now?" and recording their response by placing a mark along a 100mm VAS scale with 0mm=no pain and 100mm=extreme pain. A negative value for change from baseline indicated a reduction in pain. A greater negative value indicates a better outcome. | 26 weeks post-injection | |
Secondary | The change from baseline in Grip Strength using a hydraulic hand dynamometer at 4, 12, 18, and 26 weeks comparing the OVT group to the saline control group | Pain After Grip score was determined by asking the subject "How much pain do you have in your STUDY elbow right now?" and recording their response by placing a mark along a 100mm VAS scale with 0mm=no pain and 100mm=extreme pain. A negative value for change from baseline indicated a reduction in pain. A greater negative value indicates a better outcome. | 4,12,18 and 26 weeks post-injection | |
Secondary | The change from baseline in rescue medication consumption (acetaminophen/ paracetamol) through weeks 4-26 comparing the OVT group to the saline control group | Pain After Grip score was determined by asking the subject "How much pain do you have in your STUDY elbow right now?" and recording their response by placing a mark along a 100mm VAS scale with 0mm=no pain and 100mm=extreme pain. A negative value for change from baseline indicated a reduction in pain. A greater negative value indicates a better outcome. | 26 weeks post-injection | |
Secondary | The incidence, timing, severity, and relationship to treatment of all adverse events will be classified using MedDRA. | Pain After Grip score was determined by asking the subject "How much pain do you have in your STUDY elbow right now?" and recording their response by placing a mark along a 100mm VAS scale with 0mm=no pain and 100mm=extreme pain. A negative value for change from baseline indicated a reduction in pain. A greater negative value indicates a better outcome. | During injection, 4, 12, 18 and 26 weeks post-injection |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02304952 -
Eccentric Exercise or Radiofrequent Microtenotomy as Treatment of Lateral Epicondylalgia
|
N/A | |
Completed |
NCT02596659 -
Effectiveness of Radial Extracorporeal Shockwave Therapy on Tennis Elbow
|
N/A | |
Completed |
NCT00674622 -
Prolotherapy for the Treatment of Chronic Lateral Epicondylitis
|
Phase 2/Phase 3 | |
Completed |
NCT06206109 -
The Effect of Tendon Tears on Lateral Epicondylitis
|
||
Recruiting |
NCT04442321 -
Ultrasound-Guided Percutaneous Electrical Stimulation on Radial Nerve in Patients With Lateral Epicondylalgia
|
N/A | |
Not yet recruiting |
NCT04382144 -
Levobupivacaine Versus Liposomal Bupivacaine (Exparel®) for Treatment of Pain and Disability in Lateral Epicondylitis
|
Phase 4 | |
Recruiting |
NCT03863847 -
A Neurofeedback Treatment for Chronic Musculoskeletal Pain
|
N/A | |
Completed |
NCT04576195 -
Immediate Neurophysiological Effects of PENS on Radial Nerve in Patients With Lateral Epicondylalgia
|
N/A | |
Recruiting |
NCT02343809 -
Diacutaneous Fibrolysis on Lateral Epicondylitis
|
Phase 3 | |
Completed |
NCT05084664 -
Effect of Premodulated Current Versus Diadynamic Current On the Management of Tennis Elbow.
|
N/A | |
Completed |
NCT05039827 -
Mobilition With Movement and Soft Tissue Mobiiztion in Tennis Elbow
|
N/A | |
Recruiting |
NCT00395616 -
Comparison Between Type A Botulinum Toxin Injection and Corticosteroid Injection in the Treatment of Tennis Elbow
|
N/A | |
Completed |
NCT00130949 -
ALGRX 4975 in the Treatment of Tennis Elbow
|
Phase 2 | |
Recruiting |
NCT06116175 -
Lateral Epicondylitis Continuous Radiofrequency Microtenotomy
|
N/A | |
Recruiting |
NCT05326763 -
Functional and Electromyographical Changes After PRP or Dextrose Injection in Chronic Lateral Epicondylitis
|
Phase 3 | |
Completed |
NCT04454060 -
Study on the Development of Arthroscopic Treatment of Refractory Tennis Elbow
|
||
Enrolling by invitation |
NCT04445727 -
Efficacy of Vitamin C Supplement vs Spinal Manipulation to Treatment in Lateral Epicondylitis
|
N/A | |
Completed |
NCT04454047 -
Extracapsular Arthroscopic Treatment for Refractory Tennis Elbow——Mid-and-short Term Retrospective Study of 50 Cases
|
||
Recruiting |
NCT06382805 -
Comparison of the Effects of Kinesio Tape and High-intensity Laser Therapy in Lateral Epicondylitis
|
N/A | |
Completed |
NCT04395417 -
Injection Therapy in Patients With Lateral Epicondylitis
|
N/A |